Environmental pollution or respiratory diseases can negatively impact this function. Nearly 9 million people die prematurely each year worldwide as a result of air pollution1. In cities, air pollution increases the risk of respiratory and cardiovascular diseases and reduces life expectancy by two years2. Hundreds of millions of people suffer from chronic respiratory failure3 and the WHO predicts that COPD4 will become the third leading cause of death in the world by 2030. Pneumonia killed more than 800,000 children under five in 2017; that is one death every 39 seconds5.
Since BREATHING is so vital, we must advance research...
The Air Liquide Foundation supports fundamental research in two areas:
Open, innovative and more theoretical, it explores areas that are sometimes more hypothetical. As it is often remote from commercial applications, it tends to struggle to find funding. That makes it a perfect fit for a corporate foundation whose aim is the common good and scientific progress.
The Air Liquide Foundation can count on Air Liquide’s significant expertise in both health and environmental protection. This expertise built on a century of experience in delivering medical gases to hospitals including 30 years of home healthcare solutions for patients suffering from chronic respiratory diseases. This expertise, when combined with a robust ecosystem of the best scientific teams in Europe, acts as a powerful driver for improving our understanding of the atmospheric pollution impact on our health and developing new therapeutic pathways.
In practice, we:
1. British medical journal The Lancet 2017, 2. French national public health agency 2016, 3.World Health Organization, 4.Chronic Obstructive Pulmonary Disease, 5.World Health Organization
Air Liquide Foundation